SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear
Export (SINE) selinexor (KPT-330) in patients with metastatic castration-resistant prostate
cancer (mCRPC).